SCHEMBL1393728

SCHEMBL1393728

Oc1cc(O)cc(C=Cc2cc(O)c(O)c(O)c2)c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 3/20 0.74
TTR P02766 6/20 0.64
KDM4E B2RXH2 4/20 0.64
LMNA P02545 4/20 0.64
TP53 P04637 3/20 0.64
CYP1A2 P05177 3/20 0.64
CYP3A4 P08684 3/20 0.64
CYP2C9 P11712 3/20 0.64
HIF1A Q16665 3/20 0.64
HSD17B10 Q99714 3/20 0.64
MEN1 O00255 3/20 0.64
ALDH1A1 P00352 3/20 0.64
MAPT P10636 3/20 0.64
HPGD P15428 3/20 0.64
KMT2A Q03164 3/20 0.64
SMN1; SMN2 Q16637 3/20 0.64
ALOX12 P18054 3/20 0.64
ALOX5 P09917 3/20 0.64
PKM P14618 2/20 0.64
ALOX15 P16050 2/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1393726 1.00 LCK (0.74) LCKTTRKDM4ELMNATP53
SCHEMBL4608754 0.89 PTGS2 (0.54) LCKTTRKDM4ELMNATP53
SCHEMBL4608757 0.89 PTGS2 (0.54) LCKTTRKDM4ELMNATP53
SCHEMBL20437647 0.87 LCK (0.56) LCKTTRKDM4ELMNATP53
SCHEMBL720794 0.86 LCK (1.00) LCKTTRKDM4ELMNATP53
SCHEMBL720795 0.86 LCK (1.00) LCKTTRKDM4ELMNATP53
SCHEMBL718527 0.80 PTGS1 (0.69) LCKTTRKDM4ELMNATP53
SCHEMBL718526 0.80 PTGS1 (0.69) LCKTTRKDM4ELMNATP53
SCHEMBL2979473 0.80 LCK (0.73) LCKTTRKDM4ELMNATP53
SCHEMBL2979470 0.80 LCK (0.73) LCKTTRKDM4ELMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4436538-A1 COSMETIC OR PHARMACEUTICAL PREPARATION FOR SKIN CARE AND IMPROVING SKIN CONDITION Merryvital AG (CH) 2024-10-02 EP claimed
EP-3654929-B1 AQUEOUS COSMETIC COMPOSITION COMPRISING A PYRIDINEDICARBOXYLIC ACID DERIVATIVE AND A HYDROXYSTILBENE OREAL (FR) 2024-05-29 EP claimed
EP-4313010-A1 COMPOUNDS FOR USE IN THE TREATMENT AND PREVENTION OF COVID- 19 Szekeres, Thomas (AT) 2024-02-07 EP claimed
WO-2023094852-A1 COSMETIC OR PHARMACEUTICAL PREPARATION FOR SKIN CARE AND IMPROVING SKIN CONDITION MERRYVITAL AG (CH) 2023-06-01 WO claimed
WO-2022200086-A1 COMPOUNDS FOR USE IN THE TREATMENT AND PREVENTION OF COVID- 19 SZEKERES THOMAS (AT) 2022-09-29 WO claimed
EP-3654929-A1 AQUEOUS COSMETIC COMPOSITION COMPRISING A PYRIDINEDICARBOXYLIC ACID DERIVATIVE AND A HYDROXYSTILBENE L'OREAL (FR) 2020-05-27 EP claimed
WO-2019016153-A1 AQUEOUS COSMETIC COMPOSITION COMPRISING A PYRIDINEDICARBOXYLIC ACID DERIVATIVE AND A HYDROXYSTILBENE L'OREAL (FR) 2019-01-24 WO claimed
EP-2315583-B1 FORMULATION FOR IMPROVING THE BIOAVAILABILITY OF A HYDROPHOBIC MOLECULE YVERY (FR) 2018-05-09 EP claimed
US-20140371232-A1 CAJANINE STRUCTURE ANALOGOUS COMPOUND, PREPARATION METHOD AND USE INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2014-12-18 US claimed
EP-2796442-A1 CAJANINE STRUCTURE ANALOGOUS COMPOUND, PREPARATION METHOD AND USE Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences (CN) 2014-10-29 EP claimed
EP-1234571-A1 Topical composition containing a hydroxystilbene and a polyol L'OREAL (FR) 2002-08-28 EP claimed
US-6440433-B1 TREATING MENOPAUSAL SKIN DISORDERS; APPLYING TOPICAL MIXTURE TO IMPART AGING RESISTANCE; ACTIVATING SKIN FIBROBLAST PROLIFERATION SOCIETE L'OREAL S.A. (FR) 2002-08-27 US claimed
US-20020028852-A1 Resveratrol analogs for prevention of disease RUTGERS, THE STATE UNIVERSITY 2002-03-07 US claimed
EP-1068864-A1 Use of at least a hydroxystilbene as a glycation inhibitor L'OREAL (FR) 2001-01-17 EP claimed
EP-1064931-A1 Cosmetic composition containing at least an hydroxystilbene and ascorbic acid L'OREAL (FR) 2001-01-03 EP claimed
US-6147121-A TOPICALLY APPLYING HYDROXYSTILBENE DERIVATIVE TO TREAT SKIN AGING AND WRINKLES SOCIETE L'OREAL S.A. (FR) 2000-11-14 US claimed
US-6124364-A Desquamation/epidermal renewal of the skin and/or combating skin aging SOCIETE L'OREAL S.A. (FR) 2000-09-26 US claimed
EP-0953346-A1 Use of at least a hydroxystilbebe in a skin fortifying composition L'OREAL (FR) 1999-11-03 EP claimed
EP-0953344-A1 Use of at least one hydroxystilbene in a composition to stimulate desquamation of the skin and compositions containing it L'OREAL (FR) 1999-11-03 EP claimed
EP-0953345-A1 Use of at least a hydroxystilbene as an agent for decreasing micro-organism adhesion L'OREAL (FR) 1999-11-03 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371232-A1 CAJANINE STRUCTURE ANALOGOUS COMPOUND, PREPARATION METHOD AND USE ACHE, GAP43, LNPK LCK 224/4885TTR 1622/4885KDM4E 1489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.